Abstract: A method of reducing tumor size in a subject in need thereof, comprising administering to the subject an effective amount of cannabidiol effective to inhibit tumor growth.

Abstract: A method of reducing symptoms of a neurodegenerative disease comprising administering an effective amount of cannabidiol to a subject in need thereof to improved cognitive function and ameliorated the pathophysiology of the neurodegenerative disease.

Abstract: A method of reducing symptoms of a neurodegenerative disease comprising administering an effective amount of cannabidiol to a subject in need thereof to improved cognitive function and ameliorated the pathophysiology of the neurodegenerative disease.

Abstract: Compositions and methods for treating or reducing symptoms of COVID-19 are provided herein. An exemplary method includes administering to the subject an effective amount of cannabidiol to reduce acute respiratory distress syndrome caused by COVID-19.

Abstract: Compositions and methods for treating hair loss are provided. One embodiment provides a microneedle composition, which when administered to the skin of a subject promotes hair growth. The microneedle compositions include an effective amount of glucocorticoid-induced leucine zipper (GILZ) protein having an amino acid sequence that has 99 or 100% identity to SEQ ID NO: 1, or fragment thereof to promote hair growth when administered to the skin of the subject and a bioerodible, biodegradable, or biosorbable polymer, wherein the composition is formulated as bioerodible, biodegradable, or bioabsorbable microneedles. In one embodiment the GILZ protein or fragment thereof is conjugated to a cell penetrating peptide. The cell penetrating peptide can be TAT GRKKRRQRRRPQ (SEQ ID NO:4) or a variant thereof.

Abstract: In one aspect, the disclosure relates to pharmaceutical compositions comprising one or more cannabinoids and methods of treating and preventing migraine using the same. In one aspect, the pharmaceutical compositions can be formulated for administration by inhalation in order to rapidly access endogenous cannabinoid receptors while avoiding systemic side effects associated with oral or other routes of administration.

Abstract: Compositions and methods for treating or reducing symptoms of acute respiratory distress syndrome (ARDS) generally and COVID-19 infection in particular are provided herein. An exemplary method includes administering to the subject an effective amount of cannabichromene to reduce acute respiratory distress syndrome caused by ARDS generally and COVID-19 infection in particular.

Abstract: Glucocorticoid-induced leucine zipper protein (GILZ) peptide compositions and their methods of use in wound healing are disclosed herein. An exemplary GILZ peptide composition includes a GILZ fusion protein. The GILZ peptide compositions can be administered topically to wounds, for example in the form of a cream, ointment, or lotion. The GILZ peptide compositions can be used to treat acute wounds, induce wound healing in chronic wounds, and reduce scar formation.

Abstract: Disclosed herein are health-promoting beverages. The beverages include a plurality of components that when combined a consumed provide numerous health benefits such as, for example, treating or preventing one or more symptoms caused by a bacterial or viral infection as well as enhance immune response.

Abstract: Disclosed herein are consumable products for pets such as dogs, cats, horses, and birds the consumable products containing a cannabinoid. The consumable products disclosed herein can be formulated as chews or liquid supplements with pleasing flavors in order to encourage the pets to eat the consumable products and derive therapeutic benefits from consumption. The consumable products contain live, active cultures of probiotic microorganisms or may contain spores of probiotic microorganisms. The consumable products have anti-inflammatory effects due to the presence of the cannabinoid but are non-narcotic. Further, the consumable products serve to enhance gut health due to the presence of probiotics. The consumable products are particularly useful for treating, preventing, and eliminating side effects from various diseases and conditions as well as side effects from medication use. In some aspects, the consumable products are co-administered or co-formulated with other therapeutic agents.

Abstract: Disclosed herein are probiotic beverages containing cannabinoid. The beverages disclosed herein may be formulated as water-based drinks or yogurt drinks, for example, and contain live, active cultures of probiotic microorganisms or may contain spores of probiotic microorganisms. The beverages may additionally include prebiotic substances to enhance the growth and colonization of the probiotic microorganisms in the intestines. The beverages have anti-inflammatory effects due to the presence of the cannabinoid but are non-narcotic. Further, the beverages serve to enhance gut health due to the presence of probiotics and optional prebiotics. The beverages are, at a minimum, composed of water, a cannabinoid, a probiotic microorganism, and optionally a tea extract, but may contain other components such as prebiotics, vitamins, minerals, other nutrients, and other natural products to provide additional health benefits and/or to improve the flavor, texture, and aroma of the beverages.

Abstract: Disclosed herein are frozen consumable products containing a cannabinoid. The consumable products disclosed herein can be formulated as frozen desserts or as shelf-stable compositions that can be frozen prior to consumption. The consumable products contain live, active cultures of probiotic microorganisms or may contain spores of probiotic microorganisms. The consumable products have anti-inflammatory effects due to the presence of the cannabinoid but are non-narcotic. Further, the consumable products serve to enhance gut health due to the presence of probiotics. The consumable products are particularly useful for reducing the gastrointestinal side effects of chemotherapy.

Abstract: Compositions and methods for treating hair loss are provided. One embodiment provides a microneedle composition, which when administered to the skin of a subject promotes hair growth. The microneedle compositions includes an effective amount of glucocorticoid-induced leucine zipper (GILZ) protein or fragment thereof to promote hair growth when administered to the skin of the subject and a bioerodible, biodegradable, or biosorbable polymer, wherein the composition is formulated as bioerodible, biodegradable, or bioabsorbable microneedles. In one embodiment the GILZ protein or fragment thereof is conjugated to a cell penetrating peptide. The cell penetrating peptide can be TAT YGRKKRRQRRR or a variant thereof.

Abstract: Glucocorticoid-induced leucine zipper protein (GILZ) peptide compositions and their methods of use in wound healing are disclosed herein. An exemplary GILZ peptide composition includes a GILZ fusion protein. The GILZ peptide compositions can be administered topically to wounds, for example in the form of a cream, ointment, or lotion. The GILZ peptide compositions can be used to treat acute wounds, induce wound healing in chronic wounds, and reduce scar formation.

Abstract: A method of combining probiotic compositions with whole body vibration therapy for the treatment and inhibition of diabetes is disclosed. The disclosed methods may be used for treating diabetes, normalizing glucose metabolism, and reducing inflammation. The disclosed probiotic compositions in combination with whole body vibration are useful in the treatment and inhibition of diabetes.

Abstract: Disclosed herein are probiotic beverages containing cannabinodiol. The beverages disclosed herein may be formulated as yogurt drinks, for example, and contain live, active cultures of probiotic microorganisms. The beverages may additionally include prebiotic substances including, but not limited to, inulin to enhance the growth and colonization of the probiotic microorganisms in the intestines. The beverages have anti-inflammatory effects due to the presence of cannabinodiol but are non-narcotic. Further, the beverages serve to enhance gut health due to the presence of probiotics and prebiotics. The beverages are, at a minimum, composed of yogurt, cannabinodiol, Lactobacillus bifidus, and Lactobacillus acidophilus but may contain other components such as vitamins, minerals, other nutrients, and other natural products to provide additional health benefits and/or to improve the flavor, texture, and aroma of the beverages.

Abstract: Methods for detection and diagnosis of Sjögren's Syndrome in a subject, determining the stage or progression of Sjögren's Syndrome in a subject, determining the effectiveness of a treatment for Sjögren's Syndrome, and selecting a subject for treatment for Sjögren's Syndrome are disclosed. The methods typically include measuring the level of one or more Sjögren's Syndrome biomarkers in a biological sample obtained from a subject. Biomarkers for Sjögren's Syndrome include, but are not limited to, GADD153 and Del-1.

Abstract: Methods for detection and diagnosis of Sjögren's Syndrome in a subject, determining the stage or progression of Sjögren's Syndrome in a subject, determining the effectiveness of a treatment for Sjögren's Syndrome, and selecting a subject for treatment for Sjögren's Syndrome are disclosed. The methods typically include measuring the level of one or more Sjögren's Syndrome biomarkers in a biological sample obtained from a subject. Biomarkers for Sjögren's Syndrome include, but are not limited to, GADD153 and Del-1.

Abstract: Described herein are beverages that provide a number of heath benefits associated with elevated or high blood sugar levels. For example, the beverages are useful in potentiating insulin activity, treating hyperglycemia, and maintaining blood sugar levels in a subject afflicted with diabetes. The beverages are composed of distilled water, cinnamon extract, and sweetener. Vitamins, minerals, and nutrients can be added to the beverage to provide additional health benefits.

Abstract: Compositions for activating SGK-1 are provided. SGK-1 activators can be identified by the methods of screening provided herein. The SGK-1 activators can be used in the disclosed methods of reducing cell death and methods of treating ischemic-reperfusion injury. The ischemic-reperfusion injury can be due to a variety of complications resulting in blood loss to tissue and then the re-establishment of blood flow to the tissue.